公衆衛生77巻12号

2013年12月発行

連載 この人に聞きたい！・9

遺伝性乳がん・卵巣がん症候群(HBOC)とその予防

著者： 山内英子¹

所属機関： ¹聖路加国際病院ブレストセンター

ページ範囲：P.1006 - P.1010

はじめに

　米国の人気女優アンジェリーナ・ジョリーさんが，自身の遺伝的背景から未発症の両側乳房を予防的に切除したことから，遺伝性乳がん・卵巣がん症候群(hereditary breast and ovarian cancer syndrome;HBOC)に大きな関心が寄せられている．関心が高まり，この症候群に医療者のみならず社会が注意を払い，必要なリスクの高い人を拾い上げ，その予防策を講じること，またその体制を整えていくことは必要なことではある．しかし反対に，いたずらに不安を煽ったり，また今回のように予防的手術を選択する人の事情もわからずに批判したりするようなことは避けなければならない．一般の人々から質問を受けた時にも，HBOCに関する正確な知識を提供できるように，皆さんと学びたいと思う．

参考文献

1) Miki Y, et al:A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71, 1994

2) Wooster R, et al:Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789-792, 1995

3) Robson M, et al:Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J Med 357:154-162, 2007

4) Sugano K, et al:Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer. Cancer Sci 99:1967-1976, 2008

5) Sekine M, et al:Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families:two common founder mutations of BRCA1 in Japanese population. Clin Cancer Res 7:3144-3150, 2001

6) King MC, et al:Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2:National Surgical Adjuvant Breast and Bowel Project(NSABP-P1)Breast Cancer Prevention Trial. JAMA 286:2251-2256, 2001

7) Duffy SW, et al:Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations. Br J Cancer 86:218-221, 2002

8) Hartmann LC, et al:Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93:1633-1637, 2001

9) Rebbeck TR, et al:Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91:1475-1479, 1999

10) Evans DG, et al:Risk reducing mastectomy:outcomes in 10 European centres. J Med Genet 46:254-258, 2009

11) Skytte AB, et al:Breast cancer after bilateral risk-reducing mastectomy. Clin Genet 79:431-437, 2011

12) Kauff ND, et al:Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609-1615, 2002

13) Rebbeck TR, et al:Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616-1622, 2002

14) Rutter JL, et al:Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations:an Israeli population-based case-control study. J Natl Cancer Inst 95:1072-1078, 2003

15) Finch A, et al:Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 296:185-192, 2006

16) Domchek SM, et al:Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304:967-975, 2010

17) Bordeleau L, et al:Prognosis of BRCA-associated breast cancer:a summary of evidence. Breast Cancer Res Treat 119:13-24, 2010

18) Haffty BG, et al:Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359:1471-1477, 2002

19) Pierce LJ, et al:Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage Ⅰ/Ⅱ breast cancer. J Clin Oncol 24:2437-2443, 2006

20) Hudson KL, et al:Keeping pace with the times―the Genetic Information Nondiscimination Act of 2008. N Engl J Med 358:2661-2663, 2008